Autophagy inhibition-mediated epithelial&#8211;mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis by Hill, C. et al.
Hill et al. Cell Death and Disease          (2019) 10:591 
https://doi.org/10.1038/s41419-019-1820-x Cell Death & Disease
ART ICLE Open Ac ce s s
Autophagy inhibition-mediated
epithelial–mesenchymal transition
augments local myofibroblast
differentiation in pulmonary fibrosis
Charlotte Hill1, Juanjuan Li1, Dian Liu2, Franco Conforti3,4, Christopher J. Brereton3,4, Liudi Yao1, Yilu Zhou1,
Aiman Alzetani4,5, Serena J. Chee5,6, Ben G. Marshall 4,5, Sophie V. Fletcher4,5, David Hancock7,
Christian H. Ottensmeier 4,6, Andrew J. Steele 6, Julian Downward 7, Luca Richeldi3,4,8, Xin Lu9, Donna E. Davies3,4,10,
Mark G. Jones 3,4,10 and Yihua Wang 1,2,10
Abstract
Idiopathic pulmonary fibrosis (IPF), the prototypic progressive fibrotic interstitial lung disease, is thought to be a
consequence of repetitive micro-injuries to an ageing, susceptible alveolar epithelium. Ageing is a risk factor for IPF
and incidence has been demonstrated to increase with age. Decreased (macro)autophagy with age has been reported
extensively in a variety of systems and diseases, including IPF. However, it is undetermined whether the role of faulty
autophagy is causal or coincidental in the context of IPF. Here, we report that in alveolar epithelial cells inhibition of
autophagy promotes epithelial–mesenchymal transition (EMT), a process implicated in embryonic development,
wound healing, cancer metastasis and fibrosis. We further demonstrate that this is attained, at least in part, by
increased p62/SQSTM1 expression that promotes p65/RELA mediated-transactivation of an EMT transcription factor,
Snail2 (SNAI2), which not only controls EMT but also regulates the production of locally acting profibrogenic mediators.
Our data suggest that reduced autophagy induces EMT of alveolar epithelial cells and can contribute to fibrosis via
aberrant epithelial–fibroblast crosstalk.
Introduction
Idiopathic pulmonary fibrosis (IPF) is the most common
type of chronic, progressive fibrotic interstitial lung dis-
ease. It occurs with comparable incidence to that of sto-
mach, brain and testicular cancer1, and the median
survival of patients with IPF is only 3 years2,3. IPF is
characterised by aberrant extracellular matrix (ECM)
deposition, which leads to decreased lung compliance,
disrupted gas-exchange and ultimately respiratory failure
and death. As approved therapies only slow disease pro-
gression there is significant unmet medical need.
Evidence suggests that interacting genetic and envir-
onmental factors are crucial for the development of IPF,
with repetitive injuries to aged alveolar epithelium
thought to play an important role2. Ageing is a risk factor
for IPF, with disease incidence increasing with age3.
Decreased (macro)autophagy with age has been reported
extensively in a variety of systems and diseases4, including
IPF5–9. Autophagy is a tightly controlled, evolutionarily
conserved process for the lysosomal degradation of
cytoplasmic cargo, long-lived proteins and organelles.
Growing evidence suggests that autophagy acts as an
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adaptive response to facilitate cell survival and limit cell
death following exposure to stressful stimuli10.
Tissues from IPF patients are characterised by defective
autophagy responses5–8, although it is unclear whether
faulty autophagy exerts an effect directly, or if this change
is merely coincident with IPF. Loss of autophagy-related
protein 7 (ATG7), a ubiquitin-activating enzyme that is
essential for autophagy, has been demonstrated both
in vivo and in vitro to induce endothelial-to-mesenchymal
transition (EndMT). Autophagy inhibition, by loss of
ATG7, has been associated with changes in endothelial
cell (EC) architecture, reduced endothelial markers and
increased mesenchymal markers, whilst EC-specific Atg7
knockout mice had increased susceptibility to bleomycin
induced-fibrosis11. Furthermore, inhibition of autophagy
is sufficient to induce acceleration of both bronchial
epithelial cell senescence and differentiation of lung
fibroblasts into myofibroblasts8. Here, we report that
autophagy inhibition promotes epithelial–mesenchymal
transition (EMT) in alveolar epithelial cells. EMT is a
reversible biological process where epithelial cells gain
migratory and invasive abilities through loss of cell
polarity and cadherin-mediated cell–cell adhesion; this
process has been implicated in embryonic development,
wound healing, cancer metastasis and organ fibrosis12.
Specific transcription factors, EMT transcription factors
(EMT-TFs), including Snail, ZEB and TWIST are able to
promote the repression of epithelial features and induc-
tion of mesenchymal features13,14. We show that pro-
motion of EMT by autophagy inhibition in alveolar
epithelial cells is attained, at least in part, by increased
p62/SQSTM1 expression that induces p65/RELA
mediated-transactivation of Snail2 (SNAI2), which not
only controls EMT but also regulates the production of
locally acting profibrogenic mediators. This suggests that
autophagy inhibition-induced EMT of alveolar epithelial
cells contributes to fibrosis not only by affecting the epi-
thelial phenotype but also via aberrant
epithelial–fibroblast crosstalk.
Results
Autophagic activity is downregulated in IPF lungs
Defective autophagy responses in tissues from IPF
patients have been reported previously6,8. Similarly, we
observed evidence of autophagy inhibition as determined
by p62/SQSTM1 accumulation in lung epithelial cells in
IPF samples (Fig. 1; Supplementary Fig. S1a). p62/
SQSTM1 is a key protein involved in autophagy that
recognises cellular waste, which is then sequestered and
degraded by autophagy15. A strong staining for p62/
SQSTM1 was detected in IPF tissue within epithelial cells
of thickened alveoli septae where collagen deposition in
the interstitium was demonstrated (Fig. 1b; Supplemen-
tary Fig. S1a), as well as within fibroblastic foci (Fig. 1a). In
contrast, there was weak p62/SQSTM1 expression and
little collagen deposition detected in alveoli of control
lung tissue (Fig. 1c). Using a publicly available dataset16,
the mRNA level of SQSTM1 (p62) in IPF epithelial cells
was evaluated. It was found that SQSTM1 (p62) mRNA
expression level was reduced in IPF lungs (Supplementary
Fig. S1b) whilst its protein level as assessed by immuno-
histochemistry was increased in IPF (Fig. 1b; Supple-
mentary Fig. S1a). Given that p62/SQSTM1 protein levels
are predominantly regulated by autophagic activity17,
these results suggest that autophagic activity is down-
regulated in IPF epithelial cells.
Alteration of autophagic activity affects cellular plasticity
of alveolar epithelial cells
To investigate its role in alveolar epithelial cells,
autophagic activity was first modified using chemical
inhibitors. We treated human alveolar epithelial type II
(ATII) cells18–20 with an autophagy inhibitor, hydroxy-
chloroquine (HCQ), which is a lysosomotropic autophagy
inhibitor. HCQ treatment of ATII cells inhibited autop-
hagic activity, demonstrated by the accumulation of p62/
SQSTM1 (Fig. 2a), inhibition of lysosomal degradation by
HCQ also caused accumulation of LC3-II (Fig. 2a).
Autophagy inhibition with HCQ resulted in a down-
regulation of E-cadherin in a time-dependent manner
(Fig. 2a). Morphology changes were also observed fol-
lowing HCQ treatment with ATII cells developing an
elongated mesenchymal cell phenotype; this was accom-
panied by actin cytoskeleton reorganisation demonstrated
using filamentous actin (F-actin) staining with Phalloidin
(Fig. 2c), suggesting induction of a cellular reprogram-
ming process, EMT. A group of transcription factors,
termed EMT-TFs, are capable of inducing EMT, these
include Snail1 (SNAI1), Snail2 (SNAI2), TWIST1, ZEB1
and ZEB213, which act by binding E-boxes in the proximal
promoter of the CDH1 (E-cadherin) gene to repress its
expression. We thus investigated the impact of HCQ
treatment on the mRNA expression levels of E-cadherin
(CDH1) and EMT-TFs in ATII cells. Following HCQ
treatment of ATII cells, we observed a downregulation of
E-cadherin (CDH1), increased levels of a mesenchymal
marker Vimentin (VIM) and an EMT-TF Snail2 (SNAI2),
but not others (Fig. 2b).
To confirm our observations with HCQ, we treated ATII
cells with another autophagy inhibitor, Bafilomycin-A1
(Baf-A1), which inhibits autophagy by disrupting vesicular
acidification leading to an accumulation of mature, undi-
gested autophagosomes21. Autophagy inhibition by Baf-A1
treatment of ATII cells resulted in a similar induction of
EMT, evidenced by a reduction in E-cadherin (Supple-
mentary Fig. S2a), an increase of Vimentin (VIM) (Sup-
plementary Fig. S2b), and an upregulation of EMT-TF
Snail2 (SNAI2) (Supplementary Fig. S2b). Morphology
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changes were observed following Baf-A1 treatment of ATII
cells, with cells developing invasive phenotype when cul-
tured in Matrigel (Supplementary Fig. S2c).
We further used small interfering RNAs (siRNAs)
against autophagy-related protein 5 (ATG5) to study the
effects of inhibition of autophagic activity in ATII cells.
ATG5, a ubiquitin-protein ligase (E3)-like enzyme, is
essential for autophagy due to its role in autophagosome
elongation. ATG5 siRNA-transfection of ATII cells
inhibited autophagic activity, evidenced by the accumu-
lation of p62/SQSTM1 (Fig. 3a, c). As a result, ATG5
depletion led to a downregulation of E-cadherin at both
the mRNA and protein levels (Fig. 3a, b), an increase in
VIM (Vimentin) at mRNA level (Fig. 3b), and a
rearrangement of the F-actin cytoskeleton (Fig. 3c).
Similar results were observed in A549 alveolar epithelial
cells where autophagy inhibition by ATG5 depletion down
regulated E-cadherin levels and increased Snail2 (SNAI2)
expression (Supplementary Fig. S3a–c).
In a wound healing context, the EMT process allows
epithelial cells to adopt a more migratory mesenchymal
phenotype in order to spread rapidly and cover the
wounded area22. Therefore, a wound scratch assay was
utilised to test whether ATG5 depletion using ATG5
siRNA was sufficient to augment cell mobility. This
showed that 20 hours after creating the scratch wound,
ATG5 siRNA-transfected ATII cells had more
completely repaired the wound compared to control
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Fig. 1 p62/SQSTM1 is highly expressed in IPF fibroblastic foci and epithelial cells of thickened alveoli septae where collagen deposition in
the interstitium is also evident. Serial sections of IPF (fibroblastic foci in (a), and epithelial cells of thickened alveoli septae in (b)) or control lung
tissue (c) were stained for p62/SQSTM1 (top panel), with H&E (middle panel) or Masson’s trichrome stain (bottom panel, collagen shown in blue). n=
3. *a fibroblastic focus. Scale bars: 50 μm
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siRNA-transfected cells (Fig. 3d; P < 0.001). In addition,
we found in both the Transwell migration (Fig. 3e) and
Matrigel invasion assays (Supplementary Fig. S3d),
knockdown of ATG5 promoted cell migration and
invasion respectively.
Having examined the effects of autophagy inhibition in
ATII cells, we next evaluated the effect of autophagy
induction using Rapamycin, which inhibits mammalian
Target Of Rapamycin (mTOR)23. As predicted, following
Rapamycin treatment of ATII cells, phosphorylation levels
of mTOR were reduced (Supplementary Fig. S4a), and
autophagy activity was induced, indicated by a down-
regulation of p62/SQSTM1 and an increase in LC3-II
(Supplementary Fig. S4a). We also found an increase in
CDH1 (E-cadherin), and reductions in VIM (Vimentin)
and SNAI2 (Snail2) mRNA levels in ATII cells treated
with Rapamycin (Supplementary Fig. S4b), and these
effects were mainly via the induction of autophagy, since
knockdown of ATG5 completely abolished the changes
(Supplementary Fig. S4b).
Together, our results demonstrate that autophagic
activity is an important regulator of cellular plasticity in
alveolar epithelial cells.
Autophagy inhibition induces EMT via p62/SQSMT1-NFκB-
Snail2 pathway in alveolar epithelial cells
We recently reported that in colorectal and pancreatic
cancer cells, inhibition of autophagy induces EMT via
p62/SQSMT1-NFκB pathway24. Therefore, we investi-
gated if this pathway is involved in initiating autophagy
inhibition-induced EMT in ATII cells. Comparison of
control and HCQ-treated cells revealed that p65/RELA
accumulated in the nuclei of treated cells (Fig. 4a), indi-
cating that the NF-κB pathway is activated in ATII cells
when autophagy is inhibited. Functionally, p62/SQSTM1
or p65/RELA knockdown abolished the increase in Snail2
following autophagy inhibition by HCQ treatment in ATII
cells (Fig. 4b). Similar results were observed in A549 cells
(Supplementary Fig. S5). While knockdown of ATG5
induced EMT, as evidenced by a reduction in CDH1
Fig. 2 Autophagic activity altered by chemicals affects cellular plasticity of ATII cells. a Protein expression of E-Cadherin, Snail2, p62/SQSTM1
and LC3 in ATII cells treated with HCQ (25 μM) at indicated times. β-actin was used as a loading control. b Fold change in mRNA levels of CDH1 (E-
cadherin), VIM (Vimentin), SNAI1 (Snail1), SNAI2 (Snail2), TWIST1, ZEB1 and ZEB2 in ATII cells cultured in the absence or presence of HCQ (25 μM) for
24 hours. GAPDH-normalised mRNA levels in control cells were used to set the baseline value at unity. Data are mean ± s.d. n= 3 samples per group.
***P < 0.001. c Immunofluorescence staining of Snail2 (green) and F-actin (red) in ATII cells cultured in the absence or presence of HCQ (25 μM) for
24 h. Rhodamine-phalloidin was used to stain F-actin. DAPI (blue) was used to stain nuclei. Scale bar: 40 μm
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(E-cadherin) mRNA levels and increased SNAI2 (Snail2)
mRNA levels, subsequent depletion of RELA (p65) or
SQSTM1 (p62) (Supplementary Fig. S5a) partially or
completely abolished the increase in SNAI2 (Snail2), and
restored CDH1 (E-cadherin) expression (Supplementary
Fig. S5b). These data suggest that autophagy inhibition in
alveolar epithelial cells promotes EMT via the p62/
SQSMT1-NFκB-Snail2 pathway.
Fig. 3 Autophagy inhibition by ATG5 depletion induces EMT and cell migration in ATII cells. a Protein expression of E-cadherin, p62/SQSTM
and ATG12–ATG5 in ATII cells transfected with indicated siRNAs. β-tubulin was used as a loading control. b Fold change in the mRNA levels of CDH1
(E-cadherin), SNAI2 (Snail2) and VIM (Vimentin) in ATII cells transfected with indicated siRNAs. GAPDH-normalised mRNA levels in control cells were
used to set the baseline value at unity. Data are mean ± s.d. n= 3 samples per group. **P < 0.01. c Immunofluorescence staining of p62/SQSTM
(green) and F-actin (red) in ATII cells transfected with control or ATG5 siRNAs. Rhodamine-phalloidin was used to stain F-actin. DAPI (blue) was used to
stain nuclei. Scale bar: 40 μm. d Scratch wound assay of ATII cells transfected with control or ATG5 siRNAs. Representative images of ATII cells with the
indicated treatments at time 0 or 20 h after the scratch wound. Wounds have been artificially coloured red to aid visualisation. Scale bar: 200 μm. The
graph shows the area of a wound evaluated with ImageJ, and data are mean ± s.d. n= 3. ***P < 0.001. e Transwell migration assays in control or
ATG5-depleted ATII cells. Cells were stained with crystal violet. Scale bar: 100 μm. Data are mean ± s.d. n= 3. ***P < 0.001
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ATII cells undergoing autophagy inhibition-induced EMT
induce fibroblast activation via Snail2-regulated paracrine
signalling
Given that autophagy inhibition is able to induce EMT
in ATII cells, we wanted to determine the role of these
cells in the context of fibrosis, and whether they were
contributing to the fibroblast population directly. Com-
parison of ECM components in control or ATG5 siRNA
ATII cells demonstrated that ATII cells after autophagy
inhibition-induced EMT did not express significantly
more ECM genes (Supplementary Fig. S6). This suggested
ECM production in IPF lung tissue (Fig. 1) was unlikely
due directly to EMT but rather epithelial cells exhibiting
an indirect effect on fibrogenesis. Therefore, we investi-
gated whether ATG5-depleted ATII cells could produce
secreted factors that activate fibroblasts. We treated pri-
mary human lung fibroblasts from IPF patients (IPF
fibroblasts, IPFFs) with conditioned media (CM) from
ATII cells transfected with control or ATG5 siRNA (Fig.
5a) without or with addition of transforming growth
factor-β (TGF-β), and assessed levels of α-smooth muscle
actin (α-SMA), a marker of myofibroblast differentiation.
CM from ATII cells transfected with ATG5 siRNA
without TGF-β had minimal effect on the activation of
fibroblasts (Fig. 5b). However in IPFFs, CM from ATG5-
depleted ATII cells together with TGF-β achieved a
synergistic effect in activating fibroblasts as assessed by α-
SMA protein levels (Fig. 5b). Notably, levels of phospho-
Smad2 (p-Smad2) did not significantly change between
different CM with TGF-β treatment, suggesting α-SMA
increase may be Smad2-independent (Fig. 5b). Given the
importance of Snail2 (SNAI2) in mediating EMT by
autophagy inhibition (Fig. 5a), we hypothesised that Snail2
(SNAI2) may facilitate crosstalk by mediating paracrine
signalling from ATII cells undergoing autophagy
inhibition-induced EMT. Snail2 (SNAI2) depletion (Fig.
5a) in ATII cells eliminated the effects of CM from ATG5-
depleted ATII cells on activation of fibroblasts in the
presence of TGF-β (Fig. 5c), highlighting the importance
of Snail2 (SNAI2) as a key regulator of paracrine signalling
between alveolar cells and fibroblasts in IPF under con-
ditions where autophagy is defective.
Discussion
Fibrotic diseases are poorly characterised and lack effec-
tive treatment25, with fibrosis presenting as a pathological
feature in a range of diseases affecting many organs25,26. A
rise in the incidence of some fibrotic diseases1,3 and with
fibrogenesis being accepted as a major cause of death27; it is
evident that they are becoming an increasing healthcare
burden, requiring further research to elucidate underlying
mechanisms which drive fibrogenesis. IPF is an aging-
associated chronic, interstitial lung disease2,28–34. Treat-
ment options for patients are limited35 and the underlying
mechanisms for fibrosis are still debated36. EMT has been
suggested to have a direct role in IPF, with studies showing
co-localisation of epithelial and mesenchymal markers37–41,
and laser capture micro-dissection isolated RNA from
epithelial cells in IPF lungs confirmed expression of
mesenchymal markers42. However, lineage tracing studies
found the number of fibroblasts derived from epithelial
cells to be small43,44, and these cells were not found to co-
localise with α-SMA suggesting they did not transition to
myofibroblasts45,46. It also been proposed in a number of
systems that epithelial cells that have undergone EMT may
secrete a range of fibrogenic growth factors and cytokines,
with impaired epithelial repair leading to aberrant
epithelial–mesenchymal communication contributing to
the recruitment and activation of myofibroblasts18,47,48.
Here, we show that autophagy inhibition in ATII cells can
induce EMT, and this contributes to fibrosis via aberrant
epithelial–fibroblast crosstalk, rather than as a direct con-
tribution to the fibroblast population.
Fig. 4 Autophagy inhibition induces EMT via p62/SQSTM1-NF-κB-
Snail2 pathway in ATII cells. a Immunofluorescence staining of p62/
SQSTM1 (red) and p65/RELA (green) in ATII cells treated with
hydroxychloroquine (HCQ, 25 μM) for 24 h. DAPI (blue) was used to
stain nuclei. Scale bar: 40 μm. b Protein expression of Snail2, p65/RELA
and p62/SQSTM1 in ATII cells transfected with the indicated siRNAs
followed by treatment of HCQ (25 μM) for 24 h. For protein expression
of p62/SQSTM1, both short and long exposures (respectively) are
shown. β-tubulin was used as a loading control
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Autophagy is a tightly controlled, evolutionarily con-
served biological process where long-lived proteins and
damaged organelles are degraded. Manipulation of
autophagy is now being utilised as a therapeutic approach
in a number of fields, such as, neurodegenerative diseases
and cancer49,50. On the other hand, decreased autophagic
activity has been reported in many human diseases51,
including IPF5–8. In IPF, ageing is a main risk factor in its
development with patients under the age of 50 being
rare29. Ageing has been linked to reduced autophagy in
many contexts, including IPF5,52. Consistent with these
findings6,8 we demonstrated strong immunostaining for
Fig. 5 ATII cells undergoing autophagy inhibition-induced EMT induce fibroblast activation via Snail2-regulated paracrine signalling. a
Protein expression of E-cadherin, ATG12–ATG5 and Snail2 in ATII cells transfected with indicated siRNAs. β-tubulin was used as a loading control. b, c
Protein expression of α-SMA, Smad2 and phospho-Smad2 (p-Smad2) in IPFFs with indicated treatments. β-tubulin was used as a loading control.
Scores under the bands are relative levels when compared with indicated controls (1.0). The graphs show relative α-SMA protein levels evaluated
with ImageJ, and data are mean ± s.d. n= 3. *P < 0.05. ***P < 0.001
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p62/SQSTM1 in IPF epithelial cells of thickened alveolar
septae whilst identifying only very weak signals in the
control lung. We found significantly lower levels of
SQSTM1 (p62) mRNA in IPF epithelial cells compared to
control epithelial cells, which indicated that the increase
in p62/SQSTM1 protein levels was due to reduced
autophagic activity. Taken with previous findings6,8, these
results indicate that autophagic activity is downregulated
in IPF epithelial cells.
Whilst the concept of EMT is well established in the
context of embryonic development, it also plays a role in
in wound healing, cancer metastasis and fibrosis12. EMT
requires a complex orchestration of multiple signalling
pathways, including TGF-β, fibroblast growth factor,
Wnt/β-catenin, epidermal growth factor (EGF) and oth-
ers. Loss of E-cadherin is considered to be a fundamental
event in EMT. Snail1/2, ZEB1/2 and some basic helix-
loop-helix factors are potent repressors of E-cadherin
expression53,54. The role of EMT in cancer is detrimental
whereas in wound healing, EMT as a response to injury
can be beneficial, however, if the wound healing process is
exaggerated it may lead to fibrosis. The interplay between
autophagy and EMT have been reported in other disease
contexts55–57, with a recent study demonstrating inhibi-
tion of autophagy induces EMT via p62/SQSMT1-NFκB/
RELA pathway in RAS-mutated cancer cells24. This is
mainly via upregulation of ZEB1 and to a lesser extent via
Snail224. In contrast, in lung alveolar epithelial cells,
autophagy inhibition induces EMT in the absence of RAS
activation and is exclusively via up-regulation of Snail2
(Fig. 6a), indicating this effect is likely dependent on the
cellular context. The importance of Snail2 in IPF has been
demonstrated with Snail2 being upregulated in IPF lung
epithelial cells, but not Snail1 or TWIST1, compared to
control epithelial cells16,18. Jayachandran et al.54 reported
that Snail2-mediated EMT may contribute to the fibro-
blast pool. However, in this study, we found ATII cells
undergoing autophagy inhibition-induced EMT induce
fibroblast activation via Snail2-regulated paracrine
signalling.
In IPF it was recently reported that micro-injuries could
lead to the activation of the EGFR-RAS-ERK pathway, and
ZEB1 was demonstrated to mediate paracrine signalling18.
Similarly in renal fibrosis, tubular epithelial cells are able
to promote myofibroblast differentiation and fibrogenesis
without directly contributing to the fibroblast population
by relaying signals to the interstitium. For example, in a
murine model, damage-mediated Snail1 reactivation-
induced partial EMT and resulted in renal fibrosis, but
these cells did not contribute to myofibroblast or inter-
stitial cell population47. Conversely, EMT was inhibited
and interstitial fibrosis attenuated upon conditional
deletion of Snail1 or Twist148.
Taken together, we believe that repetitive local micro-
injuries to ageing alveolar epithelium cause persistent
activation of alveolar epithelial cells, which secrete
numerous profibrogenic factors, driving local myofibro-
blast differentiation (Fig. 6b). Thus, targeting of EMT
inducers might have therapeutic potential in fibrotic
conditions, with such therapies currently undergoing
development in the context of malignancy58,59.
Methods
Lung tissue sampling
All human lung experiments were approved by the
Southampton and South West Hampshire and the Mid and
South Buckinghamshire Local Research Ethics Committees,
and all subjects gave written informed consent. Clinically
indicated IPF lung biopsy tissue samples and non-fibrotic
control tissue samples (macroscopically normal lung sampled
remote from a cancer site) were assessed as surplus to clinical
diagnostic requirements. All IPF samples were from patients
subsequently receiving a multidisciplinary diagnosis of IPF
according to international consensus guidelines29.
Fig. 6 Autophagy inhibition-mediated epithelial–mesenchymal
transition augments local myofibroblast differentiation in
pulmonary fibrosis. Diagrams showing autophagy inhibition induces
EMT via p62/SQSMT1-NFκB-Snail2 pathway in alveolar epithelial cells
(a) and local micro-injuries to ageing alveolar epithelium causes
persistent activation of alveolar epithelial cells, which secrete
numerous profibrogenic factors, driving local myofibroblast
differentiation (b)
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Cell culture, reagents and transfections
Primary parenchymal lung fibroblast cultures were
established from IPF tissues as described previously60,61.
Fibroblasts were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% foetal bovine
serum (FBS), 50 units/ml penicillin, 50 μg/ml streptomy-
cin, 2 mM L-glutamine, 1 mM sodium pyruvate and 1×
non-essential amino acids (DMEM/FBS) (all from Life
Technologies). ATII cells18–20 were cultured in DCCM-1
(Biological Industries Ltd.) supplemented with 10% NBCS
(Life Technologies), 1% penicillin, 1% streptomycin and
1% L-glutamine (all from Sigma Aldrich). A549 cells were
cultured in DMEM (Fisher Scientific UK, 11594446)
supplemented with 10% FBS (Invitrogen) and antibiotics.
All cells were kept at 37 °C and 5% CO2. For 3D culture,
ATII cells were cultured as previously described62 in
Matrigel (BD Biosciences). Bafilomycin-A1 (Baf-A1) was
from Enzo Life Sciences. HCQ and Rapamycin were from
Sigma Aldrich. No mycoplasma contamination was
detected in the cell lines used.
siRNA oligos against ATG5 (MU-004374-04-0002),
SQSTM1 (p62) (MU-010230-00-0002), SNAI2 (Snail2)
(MU-017386-00-0002) and RELA (p65) (MU-003533-02-
0002) were purchased from Dharmacon. Sequences are
available from Dharmacon, or on request. As a negative
control we used siGENOME RISC-Free siRNA (Dharma-
con, D-001220-01). ATII and A549 cells were transfected
with the indicated siRNA oligos at a final concentration of
35 nM using DharmaFECT 2 reagent (Dharmacon).
Western blot analysis
Western blot analysis was performed with lysates from
cells with urea buffer (8M Urea, 1M Thiourea, 0.5%
CHAPS, 50 mM DTT, and 24 mM Spermine). Primary
antibodies were from: Santa Cruz (β-actin, sc-47778; E-
cadherin, sc-21791; Snail2, sc-10436), Abcam (β-tubulin,
ab6046), Cell Signalling Technology (α-SMA, 14968;
Snail2, 9585; Smad2, 5339; Phospho-Smad2, 3104;
β-tubulin, 86298; LC3, 2775; p62/SQSTM1, 5114; p65/
RELA, 8242; ATG5, 2630; mTOR, 2972; Phospho-mTOR
Ser2448, 5536), and BD Transduction Laboratories (E-
cadherin, 610405). Signals were detected using an ECL
detection system (GE Healthcare) or Odyssey imaging
system (LI-COR), and evaluated by ImageJ 1.42q software
(National Institutes of Health).
qRT-PCR
Total RNA was isolated using RNeasy mini kit (Qiagen)
according to manufacturer’s instructions and quantified
using a Nanodrop Spectophotometer 2000c (Thermo
Fisher Scientific). Real-time quantitative RT-PCR was
carried out using gene-specific primers (QuantiTect Pri-
mer Assays, Qiagen) for CDH1 (E-cadherin)
(QT00080143), SNAI1 (Snail1) (QT00010010), SNAI2
(Snail2) (QT00044128), ZEB1 (QT00008555), ZEB2
(QT00008554), TWIST1 (QT00011956), COL1A1
(QT00037793), ACTA2 (α-SMA) (QT00088102),
COL3A1 (QT00058233), FN1 (QT00038024), VIM
(QT00095795), GAPDH (QT01192646) or ACTB
(β-actin) (QT01680476) with QuantiNova SYBR Green
RT-PCR kits (Qiagen). Relative transcript levels of target
genes were normalised to GAPDH or ACTB (β-actin).
Immunofluorescence microscopy
Cells were fixed in 4% phosphate-buffered saline
(PBS)–paraformaldehyde for 15 min, incubated in 0.1%
Triton X-100 for 5 min on ice, then in 0.2% fish skin
gelatine in PBS for 1 h and stained for 1 h with an anti-E-
cadherin (1:100, BD Biosciences, 610182) or anti-p62/
SQSTM1 (1:100, BD Biosciences, 610833) or anti-Snail2
(1:100, Cell Signalling Technology, 9585), p65/RELA
(1:100, Cell Signalling Technology, 8242). Protein
expression was detected using Alexa Fluor (1:400, Mole-
cular Probes) for 20min. DAPI or TO-PRO-3 (Invitrogen)
was used to stain nuclei (1:1000). Rhodamine phalloidin
was used to visualise filamentous actin (F-actin) (Mole-
cular Probes). For immunofluorescence staining of 3D
cultures from ATII cells, spheres were fixed with 4%
PBS–paraformaldehyde for 40min, permeabilised in 0.5%
Triton X-100 for 10min on ice and stained with rhoda-
mine phalloidin for 1 h at room temperature. Spheres
were counterstained with DAPI. Samples were observed
using a confocal microscope system (Leica SP8). Acquired
images were analysed using Photoshop (Adobe Systems)
according to the guidelines of the journal.
Wound-healing migration assay
The wound-healing migration assays were done in
conjunction with siRNA transfections in ATII cells.
Seventy-two hours after siRNA transfections, confluent
monolayers of cells were wounded with a p20 pipette tip
(time 0). Phase-contrast images were taken using an
Olympus inverted microscope at time 0 or 20 h after the
scratch wound, invasive cells were evaluated by ImageJ
software (National Institutes of Health).
Transwell migration and Matrigel invasion assay
For the Transwell migration assay, Transwell mem-
branes (8-μm pore size, 6.5-mm diameter; Corning
Costar, 3422) were used. The bottom chambers of the
Transwell were filled with migration-inducing medium
(with 50% FBS). The top chambers were seeded with 1.5 ×
105 live serum-starved control or ATG5-depleted ATII
cells per well. After 24 h, the filters were fixed with 4%
paraformaldehyde for 10 min at room temperature; sub-
sequently, the cells on the upper side of the membrane
were scraped with a cotton swab. Similar inserts coated
with Matrigel (Corning, 354480) were used to determine
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invasive potential in invasion assays. Filters were stained
with crystal violet for light microscopy. Images were taken
using an Olympus inverted microscope and migratory
cells were evaluated by ImageJ 1.42q software (National
Institutes of Health).
Immunohistochemistry, haematoxylin and eosin (H/E) and
tinctorial stains
Control or IPF lung tissues were fixed and embedded in
paraffin wax; tissue sections (4 µm) were processed and
stained as previously described18. Briefly, the tissue sec-
tions were de-waxed, rehydrated and incubated with 3%
hydrogen peroxide in methanol for 10min to block
endogenous peroxidase activity. Sections were then
blocked with normal goat serum and incubated at room
temperature with a primary antibody against p62/
SQSTM1 (1:100, Progen, GP62_C), followed by a bioti-
nylated secondary antibody (1:500, Vector Laboratories
Ltd., UK); antibody binding was detected using
streptavidin-conjugated horse-radish peroxidase and
visualised using DAB (DAKO) before counterstaining
with Mayer’s Haematoxylin. For H/E stain, Shandon
Varistain 24-4 automatic slide stainer (Thermo Fisher
Scientific) was used. For tinctorial stain, Trichrome stain
(Abcam ab150686) was used according to the manu-
facturers’ instructions. Images were acquired using an
Olympus Dotslide Scanner VS110.
Statistical analysis and repeatability of experiments
Each experiment was repeated at least twice. Unless
otherwise noted, data are presented as mean and s.d., and
a two-tailed, unpaired or paired Student’s t test was used
to compare two groups for independent samples. P < 0.05
was considered statistically significant.
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